Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03684694
Title Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications

mantle cell lymphoma

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Ibrutinib + Loncastuximab tesirine-lpyl

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.